Spero therapeutics to present at cantor's global healthcare 2023 investor conference

Cambridge, mass., sept. 20, 2023 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro) (spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (mdr) bacterial infections, today announced that sath shukla, president and chief executive officer of spero therapeutics, will present and be available for one-on-one meetings at cantor fitzgerald's global healthcare 2023 investor conference, which will be held on september 26-28, 2023, at the intercontinental barclay hotel in new york, ny. details are as follows:
SPRO Ratings Summary
SPRO Quant Ranking